Vimarsana
Biggest News Aggregation in the World

Page 14 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers - Vimarsana News

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers

/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...

Medicenna Presents Phase 1/2 ABILITY Study Data - Vimarsana News

Medicenna Presents Phase 1/2 ABILITY Study Data

-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) ...

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Vimarsana News

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease ... | May 10, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims - Vimarsana News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. (“Rubius” or the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc. - Vimarsana News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY). Such...